Norepinephrine, tri-iodothyronine and insulin upregulate glyceraldehyde-3-phosphate dehydrogenase mRNA during brown adipocyte differentiation

Isabel Barroso, Begona Benito, Custodia Garcia-Jimenez, Arturo Hernandez, Maria Jesus Obregón and Pilar Santisteban

Instituto de Investigaciones Biomedicas ‘Alberto Sols’, Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid, Arturo Duperier 4, E-28029-Madrid, Spain

(Correspondence should be addressed to P Santisteban, Instituto de Investigaciones Biomedicas, CSIC/UAM, Arturo Duperier 4, 28029-Madrid, Spain; Email: psantisteban@iib.uam.es)

Abstract

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression was studied in differentiating brown adipocytes. Northern blot analysis showed that GAPDH mRNA levels increased during differentiation of precursor cells into mature adipocytes, mainly in the initial stages of the differentiation process. Insulin, tri-iodothyronine (T3) and norepinephrine, the main regulators of brown adipose tissue function, upregulated GAPDH mRNA levels, whereas retinoic acid inhibited them. The effect of insulin was present on all culture days examined, was time- and dose-dependent, and was exerted through its own receptors, as demonstrated by comparing insulin and insulin-like growth factor (IGF)-I and -II potencies in this system. Using the transcriptional inhibitor, actinomycin D, we demonstrated that T3, and to a lesser extent insulin, stabilized GAPDH mRNA. Experiments with cycloheximide indicated that both hormones require de novo protein synthesis to achieve their effects. Using cAMP analogs, we showed that the effect of norepinephrine is probably exerted through this second messenger. Co-operation was elucidated between norepinephrine- and insulin-mediated induction of GAPDH mRNA levels. In summary, we have demonstrated that GAPDH mRNA is subjected to multifactorial regulation in differentiating brown adipocytes that includes differentiation of precursor cells and the lipogenic/lipolytic regulators of the tissue.

European Journal of Endocrinology 141 169–179

Introduction

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) was first discovered as an abundant, glycolytic enzyme that catalyzes the conversion of glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate. Recent evidence demonstrated that GAPDH also participates in many other cellular processes (1). Although this enzyme has been, for some years, considered to be a non-regulated protein, expression of the GAPDH gene varies in different circumstances such as hypoxia (2), transition during the cell cycle (3), or exposure to the toxic compound, tetrachlorodibenzo-p-dioxin (TCDD) (4). The changes observed in response to insulin, serum, or epidermal growth factor have led investigators to question the use of GAPDH as a suitable control in gene regulation studies (5). More recently, other agents such as vitamin D3 (6) or glucose (7) have been added to the growing list of GAPDH gene regulators. However, transcription factors that activate the GAPDH gene promoter remain obscure, with the exception of a protein that mediates the insulin response (8, 9). In adipose tissue, GAPDH is the rate-limiting enzyme for providing lipogenic substrates in the glycolytic pathway. Spiegelman & Green demonstrated the GAPDH protein levels increase during adipose differentiation (10). Finally, GAPDH gene expression is upregulated in a model of genetically obese rats (11).

Brown adipose tissue (BAT) provides heat in facultative thermogenesis, and participates in the regulation of the energy balance in the body. In so doing, BAT accounts for the expression of the tissue-specific uncoupling protein 1 (UCP 1) that dissipates energy by uncoupling oxidative phosphorylation (12). Two other uncoupling proteins, UCP 2 and UCP 3, which have a wider tissue expression, have also been cloned (13–15). BAT is subjected to a complex neurohormonal regulation, exerted initially by the sympathetic nervous system (SNS) (16, 17) and thyroid hormones (18). Insulin (19) and retinoids (20) have also been identified as important regulators of brown adipocyte function. This tissue is closely linked to glucose/lipid metabolism, as demonstrated by three lines of evidence. First, glucose and fatty acids are the...
energy sources of BAT (21). Secondly, as fatty acids are the main energy source of BAT, lipid metabolism is essential in brown adipocytes; in these cells, both lipogenesis and lipolysis are active, and the balance between them is carefully maintained by an accurate regulation of lipogenesis- and lipolysis-related enzymes (22). Thirdly, BAT ablation results in obesity and general metabolic disorders (23). For these reasons, brown adipocytes constitute an excellent model with which to study the regulation of enzymes related to lipid metabolism.

We have chosen primary cultures of brown pre-adipocytes with the capacity to differentiate, in culture, into mature adipocytes. These cultures offer the advantage of working in a defined medium, in which it is possible to study the function of a single factor. In addition, they are subjected to the same regulators that are effective in vivo, and their results are easier to interpret, as secondary effects and tissue or blood-borne interactions are not present. Before reaching confluence, precursor cells have the morphology of mesenchymal-type cells. Once confluent, the preadipocytes differentiate into mature cells: they accumulate lipids in the cytosol, acquire the morphology typical of adipocytes, and become responsive to hormones that regulate lipid metabolism (24). The acquisition of the BAT phenotype in these cells is reflected by the expression of the differentiation marker, UCP 1 (25, 26).

In the present report, we show that GAPDH mRNA levels increase in parallel with brown adipocyte differentiation. A physiological dose of insulin induces GAPDH transcript on whichever culture day it is added. Tri-iodothyronine (T₃), another key regulator of BAT function, also upregulates GAPDH mRNA in this

Figure 1 GAPDH mRNA levels during brown preadipocyte differentiation: effect of insulin. (A) Preadipocytes were grown and differentiated into mature adipocytes as described in Materials and methods, and total RNA was extracted at the days indicated in the figure, which represent different stages of the differentiation process: day 4, preadipocytes; day 6, differentiating adipocytes; day 8, mature adipocytes. Half of the plates (+) received 4 nmol/l insulin for the last 24 h; the remaining plates (-) were incubated in the absence of insulin for the last 24 h. A representative Northern blot hybridized with the GAPDH probe and the corresponding ethidium bromide staining are shown. The graph represents the quantitation of GAPDH mRNA levels by densitometric analysis. Data are given as the mean ± s.d. from three independent experiments. Ins, insulin. (B) Brown adipocytes at day 7 after seeding were maintained in insulin-depleted medium for 24 h and then stimulated with 40 nmol/l insulin and total RNA was extracted at the times indicated. A representative Northern blot hybridized with the GAPDH probe, together with the ethidium bromide staining of the gel are shown. Densitometric quantitation was obtained; the mean ± s.d. from three different experiments are represented.
system. Both hormones require de novo protein synthesis and their effects are due, in part, to the stabilization of GAPDH transcripts. Norepinephrine, the main regulator of BAT function, also induces GAPDH gene expression, and could be acting through the cAMP signaling pathway, as cAMP analogs reproduce the induction obtained with norepinephrine. Finally, when norepinephrine, insulin, and T3 were added together in different combinations, an apparent co-operation between norepinephrine and insulin, but not T3, was observed. Overall, our data demonstrate that GAPDH mRNA increases concomitantly with brown adipocyte differentiation and exhibits a multifactorial control in this culture system.

Materials and methods

Materials

Tissue culture media were purchased from Gibco (Uxbridge, England), and newborn calf serum was from Flow (Paisley, Scotland). Guanidine HCl, 3-(N-morpholino)propanesulfonic acid (MOPS), insulin, T3, norepinephrine, 8-Br-cAMP, all-trans retinoic acid, cycloheximide and actinomycin D were provided by Sigma (St Louis, MO, USA). Insulin-like growth factors (IGFs)-I and -II were obtained from Amgen (Thousands Oaks, CA, USA). Nytran membranes were from Schleicher and Schuell (Keene, NH, USA) and the random primer kit was Pharmacia (Uppsala, Sweden). [α-32P]dCTP was purchased from ICN (Irvine, CA, USA).

RNA extraction and Northern blot analysis

At the termination of the experiments, total RNA was isolated by treatment of the cells with hot guanidine HCl extraction buffer (28). Samples of 25 μg total RNA were electrophoresed in 1% agarose gels containing 2.2 mol/l formaldehyde. RNA was blotted on nylon filters (Nytran, Schleicher and Schuell), following the manufacturer’s recommendations. Hybridization and washing steps were carried out as described elsewhere (29). A 1.0 kb Pst I fragment obtained from a human GAPDH cDNA (8) was used as probe. It hybridizes specifically with a unique 1.3 kb mRNA. The GAPDH probe was labeled by random oligopriming to a specific activity of 1 × 106 c.p.m./μg DNA. Ethidium bromide staining of ribosomal 18S was used to correct for variations in sample loading: the levels of GAPDH mRNA were visualized by autoradiography, quantitated by densitometric scanning, and corrected by the corresponding densitometric value of ribosomal 18S. The results are expressed as an intensity percentage compared with the maximum expression of each experiment. Each value represents the mean ± s.d. of three independent experiments.

Results

GAPDH gene expression is activated during brown adipocyte differentiation. Effect of insulin

After 4–5 days in culture, preadipocytes reach confluence and begin to express the marker of brown adipocyte differentiation, UCP 1 (26). From that day on, lipogenic differentiation begins, as we observed by lipid accumulation in the cytosol (data not shown), and cells are fully differentiated by days 7–8. We first studied whether the differentiation process affected GAPDH mRNA levels. To demonstrate this, precursor cells were differentiated in the absence of insulin, a known regulator of the GAPDH gene in other systems, and GAPDH mRNA levels were analyzed (Fig. 1A). As shown in this figure, GAPDH transcript was already detectable in brown preadipocytes (day 4). A low, but reproducible increase in GAPDH mRNA levels was...
detected in the early stages of lipogenic differentiation (from days 4 to 6), with no other significant change in the latest phases of differentiation (days 6 to 8). This early onset of GAPDH transcript during lipogenic activation is in agreement with similar results obtained in white adipose tissue (30).

Insulin has a key role in adipose cells, where it activates differentiation by triggering lipogenesis (19). In addition, it regulates GAPDH gene expression in a variety of systems (31, 32), including white adipocytes (8, 11). GAPDH regulation in differentiating brown adipocytes was studied in the presence and absence of insulin, to discriminate the effect due to insulin from that due to the differentiation process. Figure 1A shows that insulin (black bars) induced GAPDH mRNA levels on all culture days examined, indicating that its effect on GAPDH was direct and not a consequence of activated differentiation.

The effect of insulin was time-dependent (Fig. 1B). Cells at day 7 after seeding were grown in the absence of insulin for 24 h and then incubated with 4 nmol/l insulin for the times indicated in the figure. An effect of insulin was already observed within 2 h of treatment, and then GAPDH mRNA levels increased slowly, reaching a maximum effect by 24 h. Insulin also induced GAPDH transcript in a dose-dependent manner. Cells at day 7 after seeding were depleted of insulin for 24 h and then treated with 0.4, 4 or 40 nmol/l insulin for a further 24 h. As may be seen in Fig. 2, insulin induced GAPDH mRNA with the minimum dose used (0.4 nmol/l, which is a physiological dose for this tissue) (lane 8) and maximum effect was achieved with 40 nmol/l insulin.

Insulin may exert its effects by acting through its own or by activating IGF-I or IGF-II receptors. To characterize further the insulin regulation of GAPDH in this system, we compared the effects mediated by insulin, IGF-I and IGF-II on GAPDH gene expression. Cells at day 7 after seeding were incubated with insulin-free medium for 24 h and then treated with sub-, physiological or supra-physiological doses of all three peptides, and GAPDH mRNA levels were analyzed (Fig. 2). Whereas IGF-I and IGF-II in supra-physiological doses (100 nmol/l) efficiently induced GAPDH, an effect of insulin was observed with all doses used, even with physiological amounts (0.4 nmol/l). This finding demonstrates that insulin induces GAPDH mRNA in brown adipocytes by activating its own receptors. However, we cannot exclude the possibility that higher doses of insulin could activate IGF receptors, as even the
The highest dose of insulin tested here (40 nmol/l) did not attain a plateau effect.

The effect of insulin on GAPDH transcript was seen better during the lipogenic differentiation period (between days 5 and 9), so this was the period examined in subsequent experiments.

**T₃ induction of GAPDH mRNA levels in differentiating brown adipocytes**

Because thyroid hormones are known to be one of the main regulators of BAT function (18) and T₃ has been reported to affect gene expression in this tissue (33–35), we investigated whether this hormone had any effect on GAPDH mRNA levels in this system. Cells at day 6 after seeding were grown either in control medium or in hypothyroid medium for 24 h. Cells were then treated with 10 or 50 nmol/l T₃ for different times. As shown in Fig. 3, GAPDH mRNA levels were decreased slightly in cells grown in the absence of thyroid hormones (lane 1 compared with lane 2). In these cells, T₃ treatment not only fully restored GAPDH expression, but activated it to well above control levels. The maximum effect was achieved with 10 nmol/l T₃ for 24 h, whereas higher doses (such as 50 nmol/l T₃) did not increase the response.

**T₃ and insulin stabilize GAPDH mRNA and require de novo protein synthesis**

To examine more closely the mechanism by which insulin and T₃ stimulate GAPDH mRNA, we adopted two different approaches. In the first, cells were induced with insulin or T₃ in the presence of the inhibitor of transcription, actinomycin D. Cells at day 6 after seeding were induced to achieve maximal induction with optimal doses of T₃ or insulin (10 nmol/l T₃ or 40 nmol/l insulin respectively) for 24 h, and then were treated with 5 μg/ml actinomycin D during the times indicated in Fig. 4. The results obtained show that the half-life of GAPDH mRNA increased from 7 h to 15 h in cells stimulated with T₃, and to a lesser extent (from 7 h to 9 h) in cells treated with insulin. These data indicate that T₃ induces GAPDH mainly through stabilization of its mRNA. With regard to insulin, the observed increase in GAPDH mRNA produced by this hormone was much greater than its effect on the stabilization of GAPDH transcript. This observation suggests a direct effect of insulin on the transcriptional rate of GAPDH, which has already been reported in other systems (32, 36).

In the second approach, cells were induced with insulin or T₃ in the presence or not of 5 μg/ml
cycloheximide, an inhibitor of de novo protein synthesis. When used, cycloheximide was added 30 min before the hormones. Cells maintained in the absence of thyroid hormones or insulin for 12 h were incubated at day 5 of differentiation with 10 nmol/l T3, or at day 6 of differentiation with 40 nmol/l insulin for a further 12 h. Cycloheximide was able to inhibit the expected induction produced both by T3 (Fig. 5, lanes 2 and 4), and by insulin (lanes 5 and 6), indicating that de novo protein synthesis is required in the induction of GAPDH mRNA mediated by both hormones.

Norepinephrine stimulates GAPDH mRNA levels in brown adipocytes

Norepinephrine, released at the SNS terminals, is considered to be the main regulator of BAT thermogenic function (16). After adrenergic stimulation, norepinephrine triggers lipolysis and thermogenesis in brown adipocytes (16, 26). A cross-talk between norepinephrine and T3 pathways in this tissue has been extensively reported (37–39). In addition, there is a classical antagonism between norepinephrine and insulin actions, norepinephrine being considered as a lipolytic enzyme and insulin as a lipogenic one (40). To study the effect of norepinephrine, in addition to its possible interactions with insulin, T3, or both, cells at day 6 (in the case of insulin), or at day 7 (for T3 or norepinephrine treatments) were maintained for 24 h in control, hypothyroid medium, or in a medium depleted of most growth factors present in the serum. Cells were then treated with 4 nmol/l insulin for 24 h, or with 10 μmol/l norepinephrine or 10 nmol/l T3 for the last 4 h, so that all samples were collected at day 8 of culture. As shown in Fig. 6A, norepinephrine clearly stimulated GAPDH mRNA in control medium, its effect being similar to the induction achieved by insulin. When both hormones were added together, no increase in GAPDH mRNA levels was observed (lane 4).

In the absence of thyroid hormones (hypothyroid medium), the basal levels of GAPDH mRNA were lower than in the control medium (lane 1 compared with lane 5), because of the positive effect of T3 on this gene. Insulin induction in the hypothyroid medium was as potent as in the control medium, but the action of norepinephrine was lower (lane 3 compared with lane 7), which may suggest a permissive effect of T3 on norepinephrine action. The addition of both insulin and norepinephrine slightly increased the induction obtained with insulin alone (compare lanes 6 and 8). This effect was better observed when cells were depleted of most growth factors present in the serum (depleted medium). As shown in Fig. 6B, the addition of norepinephrine enhanced the effect of insulin (compare lanes 2 and 4), but T3 treatment did not further increase this response. Again, insulin (lane 2) and T3 alone (lane 6) induced GAPDH mRNA levels, but the addition of both hormones did not modify the effect obtained with insulin alone. From these results, we conclude that maximal induction of GAPDH is achieved when insulin and norepinephrine are present together, which may suggest a co-operation between them. Concerning T3, the results shown do not suggest a co-operation of this hormone with either norepinephrine or insulin, but...
rather reflect that thyroid hormones regulate GAPDH through a different pathway.

**cAMP analogs increase GAPDH mRNA levels**

As the effects of norepinephrine are mainly mediated through stimulation of adrenergic receptors, followed by an increase in intracellular cAMP concentrations (17, 26, 37, 41) we tested whether norepinephrine increases GAPDH mRNA through this second messenger, using the cAMP analog, 8-Br-cAMP (1 mmol/l). Cells at day 8 after seeding were treated with 1 mmol/l 8-Br-cAMP and a time-course experiment was performed. As shown in Fig. 7, GAPDH mRNA levels increased two- to threefold in the presence of this compound, with a maximum effect observed after 24 h of incubation. The same data were obtained when cells were treated with forskolin (data not shown). We conclude that an increase in intracellular levels of cAMP in our system positively regulated the expression of the GAPDH gene.

**Retinoic acid decreases GAPDH mRNA levels in brown adipocytes**

Retinoic acid is involved in a wide range of functions in the body. Its role in adipose differentiation is controversial and seems to be strictly dependent on the dose used (42, 43). In this tissue, retinoic acid regulates the expression of thermogenic genes such as UCP (20, 44), and lipogenesis-related proteins such as malic enzyme (45), or Spot 14 (34), either positively or negatively. The effect of retinoic acid on GAPDH mRNA was tested in cells growing either in control or hypothyroid medium.
for 48 h in the presence or absence of 10 nmol/l T₃, all-trans retinoic acid, or both, at the doses indicated in Fig. 8. As shown in this figure, retinoic acid slightly inhibited GAPDH transcript (lanes 5–8) only in high doses, this effect being better observed in the absence of thyroid hormones (hypothyroid medium) (lane 1 compared with lane 3). When retinoic acid was added together with T₃, the induction observed with the latter was only weakly inhibited by the retinoic acid (lane 2 compared with lane 4).

Discussion

GAPDH has been traditionally considered as a housekeeping gene, the levels of which would remain stable under different manipulations. Despite its widespread use as an internal control, GAPDH gene expression varies in different situations (3–9). This enzyme has a key role in adipocytes, in which glycolysis is an important metabolic pathway for providing lipogenic substrates. As demonstrated in differentiating white adipocytes (10) and in adipose tissue derived from genetically obese rats (11, 30), upregulation of GAPDH parallels the acquisition of the full lipogenic phenotype. In this report, we have studied GAPDH regulation in brown preadipocytes. When grown under specific conditions, these cells undergo both thermogenic and lipogenic differentiation programs (24, 26) and become responsive to hormones that regulate lipid metabolism.

As expected, GAPDH transcript increased in parallel with differentiation of the cells, mainly between days 4 and 6, when they had not yet acquired full lipogenic capacity. In later stages, GAPDH mRNA levels remained unaltered unless the cells received a lipogenic or lipolytic stimulus. This early onset of GAPDH has been reported in white adipose tissue (46) and in BAT, precedes the activation of other lipogenesis-related enzymes such as malic enzyme (33) or Spot 14 (34). As the regulation of GAPDH transcript is seen better during lipogenic differentiation (days 5–9), the effect of the main regulators of the tissue was examined in that period.

Insulin, acting through its own receptors, upregulated GAPDH mRNA levels on whichever culture day it was examined. It stabilized GAPDH transcript, and probably stimulated the transcriptional rate of the gene. This latter mechanism of action has been reported in adipocyte (8) and non-adipocyte (36) cell lines, and two different insulin response elements have been found in the human gene promoter (32). When cycloheximide was used, the inhibitor blocked the induction observed with insulin, suggesting that short-lived proteins could be required for either the transcription or the stabilization process.

In addition to insulin, GAPDH appears to be a target for T₃, norepinephrine and retinoic acid in these cells. The role of T₃ in BAT is well known (18, 47): it affects UCP 1 gene expression (35), and interacts with norepinephrine and retinoic acid (20, 35). In this report, we have shown for the first time that T₃ increases GAPDH mRNA levels in differentiating brown adipocytes. Another lipogenic gene, malic enzyme (ME), is subjected to a similar regulation by T₃ in this tissue (33). The mechanism used by T₃ for regulating both genes is also very similar, as T₃ stabilizes GAPDH mRNA and requires de novo protein synthesis, as was the case for malic enzyme. However, the existence of a thyroid hormone response element – exhaustively described for ME (48) – in the rat GAPDH promoter cannot be excluded.

Norepinephrine, considered to be the main physiological regulator of BAT, affects proliferation (49) and differentiation (17, 26) of brown preadipocytes. We have shown here that norepinephrine, probably through cAMP, upregulates GAPDH mRNA levels in differentiating brown adipocytes. This finding could be controversial in light of the well known role of norepinephrine as activator of lipolysis: two lipogenesis-related proteins.
Malic enzyme (45) and Spot 14 (34), are downregulated by norepinephrine in this system. However, Bianco et al. (50) have recently demonstrated that norepinephrine also stimulates lipogenesis in brown adipocytes, to allow the cell to recover its fat depots after heat generation by lipolysis.

When norepinephrine, insulin and T₃ are studied together, a slight loss of induction by norepinephrine is observed in the absence of thyroid hormones. This difference, although modest, could reflect a permissive role of T₃ on norepinephrine action. Interestingly, the combined action of insulin and norepinephrine suggests a co-operation between both hormones that should be studied further. This effect is specific for GAPDH and not a consequence of the tissue used, as other lipogenesis-related enzymes exhibit an opposite regulation (45).

Finally, the action of all-trans retinoic acid on GAPDH transcript was examined in this system. In brown adipocytes, retinoids regulate UCP gene expression (20, 44) and influence cell differentiation (51). As has been reported for ME (45), all-trans retinoic acid downregulates GAPDH mRNA levels in high doses.

In summary, we have shown that GAPDH mRNA expression is regulated by multiple factors in differentiating brown adipocytes: it increases with the acquisition of the fully differentiated phenotype, and is stimulated by the three major regulators of BAT function – insulin, T₃, and norepinephrine. This multifactorial regulation probably provides the cell with another means by which to control lipogenesis, and provides a strong basis on which to study the molecular mechanisms that underlie this regulation.

Acknowledgements
We thank Dr Juan A Velasco for critical reading of this manuscript. We are indebted to Dr Maria Alexander (Massachusetts General Hospital, Boston MA, USA) for the GAPDH cDNA.

This work was supported by Grants (PM97–0065) to P S and (PB95–0097) to M J O from DGICYT (Spain). IB has a fellowship from Comunidad Autónoma de Madrid (Spain).

IB and BB contributed equally to this work.

References
1 Sirover MA. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. Life Science 1996 58 2271–2277.


41 Ma SWY & Foster DO. Potentiation of in vivo thermogenesis in rat brown adipose tissue by stimulation of alpha 1-adrenoreceptors is associated with increased release of cyclic AMP. *Canadian Journal of Physiology and Pharmacology* 1984 **62** 943–948.


50 Bianco AC, Carvalho SD, Carvalho CRF, Rabelo R & Moriscot AS. Thyroxine 5’-deiodination mediates norepinephrine induced lipogenesis in dispersed brown adipocytes. *Endocrinology* 1998 **139** 571–578.


Received 8 February 1999
Accepted 27 April 1999